End-of-day quote
New Zealand S.E.
03:30:00 15/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.017
NZD
|
0.00%
|
|
+6.25%
|
-10.53%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
18.83
|
19.94
|
65.35
|
73.11
|
52.23
|
36.94
|
Enterprise Value (EV)
1 |
18.06
|
19.84
|
62.62
|
71.5
|
44.46
|
29.29
|
P/E ratio
|
-18.1
x
|
60.2
x
|
42.1
x
|
132
x
|
-18.6
x
|
-26.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.56
x
|
2.37
x
|
6.03
x
|
6.76
x
|
5.56
x
|
3.6
x
|
EV / Revenue
|
3.42
x
|
2.36
x
|
5.78
x
|
6.61
x
|
4.73
x
|
2.85
x
|
EV / EBITDA
|
-25.3
x
|
27.3
x
|
32.8
x
|
90.4
x
|
-17.9
x
|
-22
x
|
EV / FCF
|
302
x
|
-23.3
x
|
26.2
x
|
-60.5
x
|
-27.4
x
|
-2,092
x
|
FCF Yield
|
0.33%
|
-4.29%
|
3.82%
|
-1.65%
|
-3.65%
|
-0.05%
|
Price to Book
|
6.26
x
|
5.83
x
|
12.9
x
|
12.9
x
|
4.3
x
|
3.41
x
|
Nbr of stocks (in thousands)
|
11,07,654
|
11,07,654
|
11,07,654
|
11,07,654
|
12,73,802
|
12,73,802
|
Reference price
2 |
0.0170
|
0.0180
|
0.0590
|
0.0660
|
0.0410
|
0.0290
|
Announcement Date
|
18/05/18
|
24/06/19
|
28/05/20
|
27/05/21
|
31/05/22
|
25/05/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
5.285
|
8.4
|
10.83
|
10.82
|
9.4
|
10.27
|
EBITDA
1 |
-0.713
|
0.728
|
1.91
|
0.791
|
-2.49
|
-1.332
|
EBIT
1 |
-1.037
|
0.397
|
1.606
|
0.568
|
-2.715
|
-1.533
|
Operating Margin
|
-19.62%
|
4.73%
|
14.83%
|
5.25%
|
-28.88%
|
-14.92%
|
Earnings before Tax (EBT)
1 |
-1.042
|
0.381
|
1.602
|
0.564
|
-2.707
|
-1.35
|
Net income
1 |
-1.042
|
0.381
|
1.602
|
0.564
|
-2.707
|
-1.35
|
Net margin
|
-19.72%
|
4.54%
|
14.79%
|
5.21%
|
-28.8%
|
-13.14%
|
EPS
2 |
-0.000940
|
0.000299
|
0.001400
|
0.000500
|
-0.002200
|
-0.001099
|
Free Cash Flow
1 |
0.0599
|
-0.8516
|
2.394
|
-1.181
|
-1.623
|
-0.014
|
FCF margin
|
1.13%
|
-10.14%
|
22.1%
|
-10.92%
|
-17.27%
|
-0.14%
|
FCF Conversion (EBITDA)
|
-
|
-
|
125.34%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
149.44%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18/05/18
|
24/06/19
|
28/05/20
|
27/05/21
|
31/05/22
|
25/05/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
0.77
|
0.1
|
2.74
|
1.61
|
7.77
|
7.65
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
0.06
|
-0.85
|
2.39
|
-1.18
|
-1.62
|
-0.01
|
ROE (net income / shareholders' equity)
|
-29.7%
|
11.9%
|
37.8%
|
10.5%
|
-30.4%
|
-11.7%
|
ROA (Net income/ Total Assets)
|
-15.5%
|
5.46%
|
16.4%
|
4.78%
|
-15.5%
|
-7.11%
|
Assets
1 |
6.743
|
6.978
|
9.783
|
11.81
|
17.51
|
18.99
|
Book Value Per Share
2 |
0
|
0
|
0
|
0.0100
|
0.0100
|
0.0100
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0
|
0
|
Capex
1 |
0.36
|
0.08
|
0.07
|
0.1
|
0.21
|
0.05
|
Capex / Sales
|
6.72%
|
0.89%
|
0.67%
|
0.89%
|
2.27%
|
0.49%
|
Announcement Date
|
18/05/18
|
24/06/19
|
28/05/20
|
27/05/21
|
31/05/22
|
25/05/23
|
|
1st Jan change
|
Capi.
|
---|
| -10.53% | 13.27M | | +21.12% | 43.92B | | +24.56% | 23.09B | | +19.55% | 15.35B | | +13.17% | 13.61B | | +45.90% | 12.02B | | -10.14% | 7B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.07% | 5.6B |
Generic Pharmaceuticals
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly** -40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff** BENEFIT NOW**0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
|